UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Oncology Peer Reviewers

Sanjiv S Agarwala, MD

Professor of Medicine

Temple University School of Medicine

Chief of Oncology & Hematology

St Luke’s Cancer Center

Disclosure: Nothing to disclose

Jose Banchs, MD, FACC, FASE

Director of Echocardiography

Associate Professor of Medicine

Cardiology Department

University of Texas

MD Anderson Cancer Center

Disclosure: Nothing to disclose

Sally Y Barbour, PharmD, BCOP, CPP

Clinical Oncology Pharmacist

Duke Comprehensive Cancer Center

Disclosure: Consultant/Advisory Boards: Genentech, Taiho, Teva, Astra Zeneca [EGFR drugs in lung cancer (trifuridine/tipiracil)].

Aditya Bardia, MD, MPH

Attending Physician

Massachusetts General Hospital Cancer Center

Assistant Professor of Medicine

Harvard Medical School

Disclosure: Consultant/Advisory Boards: Novartis [Breast cancer (Letrozole)]; Pfizer [Breast cancer (Exemestane)].

Emily Bergsland, MD

Professor of Medicine

University of California San Francisco

Disclosure: Grant/Research/Clinical Trial Support: Lexicon [Carcinoid (telotristat)]; Merck [Carcinoid/panNET (Pembrolizumab)]; Novartis [Carcinoid/pNET]. Consultant/Advisory Board: Lexicon [Carcinoid (telotristat)]; Ipsen [ Neuroendocrine tumors (lanreotide)]; Exelixis [Carcinoid/panNET (cabozantinib)].

Lawrence Blaszkowsky, MD

MGH Cancer Center

Disclosure: Nothing to disclose

Linda D Bosserman, MD, FACP

President and Medical Oncologist

Wilshire Oncology Medical Group, Inc

Disclosure: Speaker's Bureau: Genentech [oncology value panel]; Association of Managed Care Pharmacy [value in specialty pharmacy]; PER [case studies and value talks]; Association of Nurse Navigators [Value-based cancer care (talk)]; Pfizer [Value-based cancer and breast care (None)]. Consultant/Advisory Boards: Pfizer [Biosimilars for Her2 and breast cancer]; Anthem Blue Cross Wellpoint [Breast cancer standards (None)]; American Society of Breast Surgeons [Breast cancer value-based care (None)]; GSK [Cancer care (None)]; Genentech/Roche [Breast cancer (None)]; ACCC [Value-based cancer care (None)]; Novartis [ Breast cancer value-based care (None)]; Sandox-Novartis [Value-based breast cancer care (None)]. Employment: City of Hope Medical Foundation [value based care initiatives]; Front Line Medical Communications Inc [editor].

John Buatti, MD

Professor of Radiation Oncology

University of Iowa

Disclosure: Nothing to disclose

Mark Buyyounouski, MD, MS

Associate Professor

Stanford University

Department of Radiation Oncology

Director, Genitourinary Cancers

Disclosure: Nothing to disclose

George P Canellos, MD

Editor-in-Chief — Oncology

Section Editor — Miscellaneous Tumors

Professor of Medicine

Harvard Medical School

Disclosure: Nothing to disclose

Shamus Carr, MD, FACS

Assistant Professor of Surgery

University of Maryland School of Medicine

Disclosure: Nothing to disclose

Richard J Cohen, MD, FACP

Clinical Professor of Medicine

University of California, San Francisco

Disclosure: Nothing to disclose

Robert L Coleman, MD

Professor & Vice Chair

Clinical Research

Ann Rife Cox Chair in Gynecology

Department of Gynecologic Oncology

University of Texas MD Anderson Cancer Center

Disclosure: Grant/Research/Clinical Trial Support: Merck, Oncomed, Janssen, Clovis, Astrazeneca, Genentech/Roche, Abbvie [ovarian, uterine, cervix (pembrolizumab, demcizumab, trabectedin, rucaparib, olaparib, veliparib, bevacizumab, emactuzumab, durvalumab, tremelumumab, nivolumab, selumetinib, everolimus, ribociclib, AZD-1775)]. Consultant/Advisory Boards: Merck, Oncomed, Janssen, Clovis, Astrazeneca, Genentech/Roche, Abbvie, Bayer, immunogen [ovarian, uterine (pembrolizumab, demcizumab, trabectedin, rucaparib, olaparib, veliparib, bevacizumab, emactuzumab, AZD-1775, IMGN-853)].

A Dimitrios Colevas, MD

Associate Professor of Medicine

Stanford University Medical Center

Disclosure: Grant/Research/Clinical Trial Support: BMS [head and neck (nivolumab)]; Astra Zeneca [head and neck (durvalumab, tremelimumab); Regeneron [squamous cell cancer skin (REGN2810)]; Fourty Seven [generic ph 1 (Hu5F9-G4)]; Novartis [ameloblastoma (dabrafenib, trametinib)]; IRX [head and neck (IRX-2 Regimen)]; Merck [basal cell cancer (pembrolizumab)]; Celldex [head and neck (varlilumab)].

Siamak Daneshmand, MD

Associate Professor of Urology

Director, Center for Urologic Oncology

University of Southern California

Disclosure: Nothing to disclose

Laura A Dawson, MD

Professor

Department Radiation Oncology, University of Toronto

Radiation Medicine Program, Princess Margaret Cancer Centre

Disclosure: Consultant/Advisory Boards: Merck [Hepatocellular carcinoma]. Patent Holder/Lisensure: Raysearch [Image registration (Radiation planning systems may include image registration tools)].

Jennifer F De Los Santos, MD

Associate Professor

Department of Radiation Oncology

University of Alabama at Birmingham

Disclosure: Nothing to disclose

Shrina Duggal, PharmD, BCOP

Clinical Pharmacy Specialist

UPMC Cancer Centers

Disclosure: Speaker’s Bureau: Incyte [Gastrointestinal cancer (Ruxolitinib)]; Boehringer Ingelheim [Gastrointestinal cancer (Afatinib)]; Pfizer/Astellas [Gastrointestinal cancer (Enzalutamide)].

Anthony Elliott, PharmD

Duke University Hospital

Disclosure: Nothing to disclose

Katherine Evans, PharmD

Director, Pharmacy Technology

Cape Fear Community College

Disclosure: Nothing to disclose

Shelly A Fallo, BS, RPh

Clinical Pharmacy Specialist of Oncology

Department of Pharmacy Services

Tufts Medical Center

Disclosure: Nothing to disclose

Karen M Fancher, PharmD, BCOP

Clinical Pharmacist

Blood & Marrow Transplantation

H Lee Moffitt Cancer Center and Research Institute

Disclosure: Nothing to disclose

Heidi D Finnes, PharmD, BCOP

Assistant Professor of Pharmacy

Mayo Clinic College of Medicine

Disclosure: Nothing to disclose

Harold Frucht, MD

Associate Professor of Clinical Medicine

College of Physicians and Surgeons, Columbia University

Disclosure: Nothing to disclose

Thomas Galloway, MD

Assistant Professor

Department of Radiation Oncology

Fox Chase Cancer Center

Disclosure: Nothing to disclose

Jennifer Suzanne Gass, MD, FACS

Chief of Surgery

Breast Fellowship Director

Program in Women’s Oncology

Women and Infants’ Hospital

Associate Professor of Surgery

Associate Professor of Obstetrics and Gynecology

Disclosure: Nothing to disclose

Geoffrey T Gibney, MD

Lombardi Comprehensive Cancer Center

Medstar Georgetown University Hospital

Disclosure: Speaker's Bureau: Merek [melanoma (pembrolizumab)]; Genentech [melanoma pathways (non-branded)]. Consultant/Advisory Boards: Novartis; Genentech [melanoma (dabrafenib, trametinib)].

Timothy D Gilligan, MD

Associate Professor of Medicine

Cleveland Clinic Lerner College of Medicine

Vice-Chair for Education

Cleveland Clinic Taussig Cancer Institute

Director of Coaching, Center for Excellence in Healthcare Communication

Cleveland Clinic

Disclosure: Nothing to disclose

Stephen L Graziano, MD

Professor of Medicine

SUNY Upstate Medical University

Disclosure: Nothing to disclose

Robert I Haddad, MD

Associate Professor of Medicine

Harvard Medical School

Disclosure: Grant/Research/Clinical Trial Support: BMS; Merck; Astra Zeneca; Celgene [Head and neck cancer clinical trials support to institution (None)]. Consultant/Advisory Boards: BMS; Astra Zeneca; Merck; Pfizer; Eisai [Head and neck cancer clinical trials (None)].

R Donald Harvey, PharmD, FCCP, BCPS, BCOP

Assistant Professor of Hematology/Medical Oncology

Director of Phase I Program

Emory University/Winship Cancer Institute

Disclosure: Nothing to disclose

Thomas J Herzog, MD

Clinical Director

University of Cincinnati Cancer Institute

Disclosure: Consultant/Advisory Boards: AstraZeneca; J & J; Roche; Clovis; Tesaro [Ovarian cancer (Olaparib, PLD, bevacizumab, rucaparib, niraparib)].

Warner K Huh, MD

Margaret Cameron Spain Chair in Obstetrics/Gynecology

Professor, Division of Gynecologic Oncology

Senior Scientist, UAB Comprehensive Cancer Center

Disclosure: Consultant/Advisory Boards: Merck [Cervical cytology (HPV vaccines)]; Intuitive Surgical (Robotic Surgery); LICOR (fluorescence imaging); InCellDx (cervical cancer screening).

Gregory P Kalemkerian, MD

Professor of Medicine

Co-Director, Thoracic Oncology

University of Michigan Medical Center

Disclosure: Grant/Research/Clinical Trial Support: Takeda Pharmaceuticals/Millennium [Lung cancer (Alisertib)]; Pfizer [Lung cancer (Crizotinib)]; Novartis [Lung cancer (Dabrafenib/trametinib)]; Merck [Lung cancer (Pembrolizumab)]; OncoMed Pharmaceuticals [Lung cancer (OMP-59R5)]; Astex Pharmaceuticals [Lung cancer (AT-13387)]. Consultant/Advisory Boards: Takeda Pharmaceuticals, BioMed Valley Discoveries, Esperion [drug development and safety analysis].

Sara S Kim, BS, PharmD, BCOP

Clinical Oncology Pharmacy Specialist

The Mount Sinai Medical Center

Disclosure: Nothing to disclose

Jeffrey Kirshner, MD

Principal Investigator, HOACNY CCOP

Director of Research and Partner

Hematology Oncology Associates of Central NY

Clinical Associate Professor

Department of Medicine

Upstate Medical University, Syracuse, NY

Disclosure: Nothing to disclose

Laura A Lambert, MD

Assistant Professor of Surgery

Director of Peritoneal Surface Malignancy Program

UMass Memorial Medical Center

Disclosure: Nothing to disclose

Robert D Legare, MD

Director, Breast Health Center

Director, Cancer Risk Assessment and Prevention Program

Associate Professor Obstetrics, Gynecology and Medicine

Warren Alpert Medical School

Brown University

Disclosure: Nothing to disclose

Ellis Levine, MD

Associate Professor of Medicine

State University of New York at Buffalo/Roswell Park Cancer Institute

Disclosure: Nothing to disclose

Emily Mackler, PharmD, BCOP

Clinical Pharmacist in Hematology/Oncology

University of Michigan Hospitals and Health Centers

Disclosure: Consultant/Advisory Board: NCCN (neutropenic fever, chemotherapy templates).

Martin A Martino, MD

Associate Professor

Department of Ob/Gyn

Division of Gynecologic Oncology

University of South Florida

Disclosure: Consultant/Advisory Boards: Medtronic [Gynecologic cancers.]

Jacqueline P Masker, PharmD

Duke University Hospital

Disclosure: Nothing to disclose

Mary S McCabe, RN, MA

Clinical Director, Survivorship Center

Memorial Sloan-Kettering Cancer Center

Disclosure: Nothing to disclose

Carolyn McCourt, MD

Assistant Professor

Division of Gynecologic Oncology

Department of Obstetrics & Gynecology

Washington University School of Medicine

Disclosure: Consultant/Advisory Boards: Genentech [Ovarian and cervical cancer (Bevacizumab)].

Matthew L Meyerson, MD, PhD

Professor of Pathology

Dana-Farber Cancer Institute and Harvard Medical School

Disclosure: Consultant/Advisory Boards: Origimed [Cancer diagnosis]. Equity Ownership/Stock Options: Origimed [Cancer diagnosis].

David Mutch, MD

Professor and Division Chief, Obstetrics & Gynecology, Gynecologic Oncology

Washington University School of Medicine

Disclosure: Speaker's Bureau: Clovis Oncology [Ovarian cancer (Rucaparib)]; AstraZeneca [Ovarian cancer (Olaparib)].

Jim Natale, PharmD, BCOP

Clinical Pharmacy Specialist

UPMC Cancer Centers

Disclosure: Speaker's Bureau: Eisai [CINV (Aloxi)]; Merck [Lung cancer (Keytruda)]; BMS [Lung cancer (Opdivo)].

Larissa Nekhlyudov, MD, MPH

Section Editor — Cancer Survivorship

Associate Professor

Department of Medicine

Brigham & Women’s Hospital

Harvard Medical School

Disclosure: Nothing to disclose

Scott Okuno, MD

Professor of Oncology

Division of Medical Oncology

Mayo Clinic

Disclosure: Other Financial Interest: AXIS Medical Education Faculty [certified educational activities].

Bert H O'Neil, MD

The Jackie and Joseph Cusick Professor of Oncology

Indiana University Simon Cancer Center

Disclosure: Consultant/Advisory Boards: Bayer [GI (regorafenib)]; Genentech [GI (bevacizumab, cobimetinib)]; Amgen [GI tumors (talimogene laherpravec); CRC (panitumumab)]; Merrimack [pancreatic cancer (Nal-IRI)].

David F Penson, MD, MPH

Professor of Urologic Surgery

Director of Vanderbilt Center for Surgical Quality and Outcomes Research

Disclosure: Consultant/Advisory Boards: Medivation; Astellas; Dendreon [Prostate cancer (Enzalutamide, sipuleucel-T)].

Sandro V Porceddu, MD

Radiation Oncologist, Princess Alexandra Hospital

Associate Professor, University of Queensland

Disclosure: Nothing to disclose

Daniel Przybysz, MD

Radiation Oncology

Siteman Cancer Center

Washington University in St. Louis

Disclosure: Nothing to disclose

David I Quinn, MBBS (Hons I), PhD, FRACP, FACP

Associate Professor of Medicine

University of Southern California Norris Cancer Center

Keck School of Medicine

Disclosure: Grant/Research/Clinical Trial Support: Millenium [Renal cell cancer (Tak700)]; Genentech [Renal cell carcinoma (Avastin, atezoluzimab)]; Glaxo Smith Kline/Novartis [Urothelial cancer (Everolimus, zometa, pazopanib)]. Consultant/Advisory Boards: Pfizer [Renal cell carcinoma (Sunitinib, axitinib, temsirolimus)]; Novartis [Renal cell carcinoma, prostate (Everolimus, zometa)]; Genentech [Bladder cancer, renal cell carcinoma (Atezoluzimab, bevacuzimab)]; Bayer [Renal cell carcinoma, prostate cancer (Radium 223, sorafenib)]; Dendeon [Prostate cancer (Sipuleucel-T)]; Astellas [Prostate cancer (Enzalutamide)]; BMS [Renal cancer, bladder cancer (Nivolumab)]; Merck Sharp Dohme [Bladder cancer, renal cancer (Pembroluzimab)]; Exelexis [Renal cell carcinoma (Caboxantinib).

Valerie Relias, PharmD, BCOP

Clinical Pharmacy Specialist

Assistant Professor of Medicine

Division of Hematology/Oncology

Tufts Medical Center

Disclosure: Speaker's Bureau: Genentech [CLL/indolent lymphoma (Obinutuzumab).

Jerome P Richie, MD, FACS

Section Editor — Cancer of the Urethra, Penis, and Ureter; Urologic Surgery; Prostate Cancer

Elliott Carr Cutler Professor of Surgery

Harvard Medical School

Disclosure: Nothing to disclose

Tina Rizack, MD, MPH

Alpert Medical School of Brown University

Disclosure: Nothing to disclose

David I Rosenthal, MD

Director

Head and Neck Translational Research

Professor

The University of Texas MD Anderson Cancer Center

Disclosure: Greant/Research/Clinical Trail Support: Merck Serono KGA [Head and neck cancer (Cetuximab)]. Consultant/Advisory Boards: Merck Serono KGA [Head and neck cancer (Cetuximab)].

Howard Safran, MD

Associate Professor of Medicine

Brown University Oncology Group

Disclosure: Nothing to disclose

Walter M Stadler, MD, FACP

Professor

University of Chicago

Disclosure: Grant/Research/Clinical Trial Support: Astra-Zeneca [Renal cancer (savolitinib)]; BMS [Renal cancer (Nivolumab)]; Boehringer-Ingelheim [Bladder (Afatanib)]; Dendreon [Prostate cancer (Sipuleucel-T, investigational bladder cancer drug)]; Exilixis [Renal cancer (Cabozantinib)]; Novartis [Renal cancer (Pazopanib; everolimus)]; Genentech [Bladder cancer (Atezolizumab)]; Jansen [Prostate cancer (Abiraterone)]; Johnson & Johnson [Bladder cancer (Investigational FGFR inhib)]; Merck [Bladder cancer (Pembrolizumab)]; Millenium [Prostate cancer (Enzalutamide)]; Pfizer [Renal cancer (Sunitinib; axitinib)]. Speaker's Bureau: CME innovations; CME Network; Dava Oncology, Research-to-Practice; Medical Communications Media [Bladder, kidney, prostate cancer CME (Standard of care drugs)]. Consultant/Advisory Boards: Astra-Zeneca [Bladder cancer (DSMB)]; Caremark/CVS [formulary advice]; Bristol-Myers-Squibb [Renal Cancer (Immunotherapy development)]; Bayer [Prostate Cancer (DSMB)]; Genentech [Bladder cancer (atezolizumab development)]; Sotio [Prostate cancer (DSMB chair for novel immunotherapy)]; Pfizer [Renal cancer (Utilization of sunitinib and axitinib)].

Ashley Stuckey, MD

Program in Women’s Oncology

Gynecologic Oncology and Breast Surgery

Women & Infants’ Hospital of Rhode Island

Assistant Professor of Obstetrics & Gynecology

The Warren Alpert Medical School of Brown University

Disclosure: Nothing to disclose

Stephanie D Sutphin, PharmD, BCOP

Hematology/Oncology Pharmacy Specialist

University of Kentucky HealthCare

Adjunct Assistant Professor

College of Pharmacy

Disclosure: Consultant/Advisory Board: Seattle Genetics [Hodgkins (Brentuximab)], Amgen [Biosimilars (Neupogen, Neulasta)].

William D Tap, MD

Section Chief, Sarcoma Oncology

Memorial Sloan Kettering Cancer Center

Disclosure: Consultant/Advisory Boards: Blueprint Medicines [Sarcoma (BLU-285)]; Daiichi Sankyo [Sarcoma (Pexidartinib)]; Eisai [Sarcoma (Eribulin)]; Eli Lilly [Sarcoma (Olaratumab, Abemaciclib, Ly1309478)]; EMD Serono [Sarcoma (Exofosfamide)]; Plexxikon [Sarcoma (PLX9486)]; Novartis [Sarcoma (Votrient)]; Janssen [Sarcoma (Trabectadin)], Immune Design (CMB305)].

Premal H Thaker, MD

Assistant Professor in Gynecologic Oncology

Washington University School of Medicine

Disclosure: Grant/Research/Clinical Trial Support: Merck [Uterine Cancer (Pembrolizumab)]. Speaker’s Bureau: Zoll[Sudden cardiac death (Life vest);Aralez Pharmaceuticals (yosprala)]. Consultant/Advisory Boards: Celsion [Ovarian Cancer (GEN-1 immunotherapy)].

Evan Tong, PharmD

Duke University Hospital

Disclosure: Nothing to disclose

Tiffany Traina, MD

Assistant Attending Physician

Breast Cancer Medicine Service

Assistant Professor in Medicine

Weill Cornell Medical College of Cornell University

Disclosure: Grant/Research/Clinical Trial Support: Medivation [Breast cancer (Enzalutamide)]; Eisai [Breast cancer (Eribulin)]; Pfizer [Breast cancer (Palbociclib, enzalutamide)]; Myriad Genetics [Breast cancer (HRD assays)]; Innocrin Pharma [Breast cancer (Seviteronel)]; AstraZeneca [Breast cancer (Bicalutamide, olaparib)]; Astellas Pharma [Breast cancer (Enzalutamide)]; Lilly [Breast cancer (Notch inhibitor)]. Speaker's Bureau: Genentech/Roche [Breast cancer (Pertuzumab, TDM1)]; Eisai [Breast cancer (Eribulin)]; Medivation [Breast cancer (Enzalutamide)]; Pfizer [Breast cancer (Palbociclib, enzalutamide)]; AstraZeneca [Breast cancer (Olaparib, bicalutamide)]; Bayer [Breast cancer (IMMU132)]; Immunomedics [Breast cancer (IMMU132)]; Merck [Breast cancer (Pembrolizumab)]; Astellas Pharma [Breast cancer (Enzalutamide)]; Puma Biotechnology [Breast cancer (Neratinib)]; Advaxis [Breast cancer]; Celgene [Breast cancer (nab-paclitaxel)]; Innocrin Pharma [Breast cancer (Seviteronel)]; Genomic Health [Breast cancer (OncotypeDx)].

Nicholas Vogelzang, MD

Section Editor — Prostate Cancer

Professor of Medicine

University of Nevada School of Medicine

US Oncology Research

Disclosure: Speaker's Bureau: Pfizer [Kidney cancer (Sunitinib, axitinib)]; Bayer [Prostate cancer (Radium 223)]; Novartis [Kidney cancer, PNET (Pazopanib, everolimus); Sanofi [Prostate cancer (Cabazitaxel)], BMS [Kidney cancer (BMS-nivolumab)]; Genentech/Roche [Bladder cancer (Atezolizumab); Astra Zeneca {Bladder cancer (durvalumab)] Consultant/Advisory Boards: Amgen [Prostate cancer (Denosumab)]; Bayer [Prostate cancer (Radium 223)]; Pfizer [Kidney cancer (Sunitinib, axitinib)]; Novartis [Kidney cancer, PNET (Pazopanib, everolimus)]; Sanofi [Prostate cancer (cabazitaxel)]; BMS [Kidney cancer (BMS-nivolumab)]; Genentech/Roche (Bladder cancer (Atezolizumab)]; Astra Zeneca {Bladder cancer (durvalumab)] Exelexis [Kidney cancer (Cabozantinib)]; Clinical Care Options, Cerulean [Kidney cancer (Liposomal irinotecan)]; Dava Oncology/PER; Dendreon; Medivation/Astellas [Prostate (Enzalutamide)], Janssen [Prostate cancer (Abiraterone,apalutamide)]; Heron [Nausea control (Liposomal granisetron)]; Eisai [Kidney cancer (Levantinib)]; Agensys [Kidney cancer (New targeted agent)]; Boehringer Ingelheim [Mesothelioma (Nerantinib)]. Employment: US Oncology [GU research (none)]. Equity Ownership/Stock Options: Caris [Genetic testing for cancer (none)].

Ageliki G Vouyouka, MD, FACS

Associate Professor in Surgery

Associate Professor in Radiology

Mt Sinai Medical Center/ Icahn School of Medicine

Disclosure: Nothing to disclose

Antonio C Wolff, MD, FACP

Professor of Oncology

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Disclosure: Grant/Research/Clinical Trial Support: Myriad [Breast cancer (HRD assay)]. Patent Holder: cMethDNA [Breast cancer (Breast cancer methylation)].

Jason D Wright, MD

Sol Goldman Associate Professor of Obstetrics and Gynecology

Chief, Division of Gynecologic Oncology

Columbia University College of Physicians and Surgeons

Disclosure: Consultant/Advisory Boards: TheVax Genetics [Human papillomavirus (Therapeutic human papillomavirus vaccine)]; Tesaro [Gynecologic cancer (Drug development)]; Clovis Oncology [Gynecologic cancer (Drug development)].